<DOC>
	<DOCNO>NCT02447809</DOCNO>
	<brief_summary>Clopidogrel important anti-platelet agent.However , 30 % coronary artery disease patient present clopidogrel low response ( CLR ) .Previous study show cardiovascular event ratio CLR patient 4.4 time normal responder . It known plasma platelet miRNAs determine different disease status platelet release megakaryocyte , platelet miRNAs adjust expression platelet 's receptor proteins.The purpose study find multiple platelet miRNAs involve development CLR , platelet miRNAs cause CLR adjust expression key receptor proteins ADP activate pathway consequently reduce response clopidogrel . The CLR detect light transmission aggregometry ( LTA ) vasodilator-stimulated phosphoprotein phosphorylation ( VASP-P ) . Differential expression plasma platelet miRNAs profile CLR patient screen deep sequencing validate investigate association plasma platelet miRNAs profile CLR well patient ' prognosis.The study result would serve marker individualize anti-platelet treatment , supply new target treatment coronary artery disease .</brief_summary>
	<brief_title>Plasma Platelet microRNAs Clopidogrel Low Response Patients</brief_title>
	<detailed_description>A multiphase , case-control study design identify plasma platelet miRNAs surrogate marker CLR . All patient take 300mg load dose clopidogrel plus 100mg daily ASA 75mg daily clopidogrel admission . Patients recruit percutaneous coronary intervention ( PCI ) . Light transmittancy aggregation ( LTA ) response 5Î¼M ADP measure 5 day take load dose clopidogrel.Than CLR patient select . In initial biomarker-screening stage , plasma platelet sample 20 CLR patient 20 control underwent Solexa sequence identify miRNAs show significant difference CLR case match control . Subsequently , perform biomarker confirmation analysis hydrolysis probe-based RT-qPCR assay refine number plasma platelet miRNAs CLR signature . This analysis carry 2 phase : ( ) biomarker-selection phase , plasma platelet sample 20 CLR patient 20 control individual form training set , ( b ) biomarker-validation phase , plasma platelet sample additional 80 CLR patient 80 control form validation set .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients receive stent implantation ; Patients take 100mg daily ASA 75mg daily clopidogrel Patient age &gt; 18 year &lt; 80 year old ; Signed inform consent Allergy intolerance ASA , clopidogrel ; Patients plan take warfarin drug potentially could interfere antiplatelet effect ASA , clopidogrel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>microRNA</keyword>
	<keyword>Platelet</keyword>
	<keyword>Clopidogrel low response</keyword>
</DOC>